Treatment
LY4395089 clinical trials
We’re tracking 2 recruiting studies that include LY4395089, each written for real people, not researchers, below.
Recruiting studies
- NCT07483099RecruitingPhase 2
Study of two drugs for Crohn's disease
This trial tests if taking a new drug (LY4395089) with mirikizumab works better than mirikizumab alone for adults with Crohn's disease. It also looks at the safety of these treatments.
Scottsdale, ArizonaAges 18–80 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Scottsdale, ArizonaAges 18–80
Common questions
- Are there clinical trials studying LY4395089?
- Yes. Clin2 currently lists 2 recruiting studies that include LY4395089, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a LY4395089 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is LY4395089 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether LY4395089 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.